Intro Widget

The Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed journal that publishes on all aspects of tumor immunology and cancer immunotherapy, aiming to enrich communication and advance scientific understanding in this rapidly evolving field. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and improve the lives of patients with cancer, SITC will provide members with a 50% discount on article processing charges for all member-authored 2020 publications.

COVID-19: A Message from BMJ

Impact Factor
8.728

JITC and BMJ: A New Partnership

The Society for Immunotherapy of Cancer is pleased to announce that the Journal for Immunotherapy of Cancer is now published by BMJ. As we move into the new year with our new strategic partner, we look forward to launching a number of exciting initiatives that will expand our journal's scope, diversify its content, and expand its readership. 

Altmetrics

About SITC

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

 

Learn more about the SITC’s mission and explore the cancer immunotherapy community at SITC Cancer Immunotherapy CONNECT.